# BioAge Labs, Inc.: financial statements, quarterly

BIOA · Nasdaq · CIK 1709941 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bioa.md) · [Financials](/companies/bioa/financials.md) · [Filings](/companies/bioa/filings.md) · [Insiders](/companies/bioa/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bioa/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0000950170-25-104176.md) | [0.0](/filings/0001193125-25-270012.md) | [0.0 d](/filings/0001193125-26-120873.md) | [1.5](/filings/0001193125-26-213466.md) | [2.4](/filings/0001193125-26-335407.md) | [2.1](/filings/0001193125-25-270012.md) | [3.1 d](/filings/0001193125-26-120873.md) | [2.8](/filings/0001193125-26-213466.md) | [2.5](/filings/0001193125-26-335407.md) |
| Research and development | $m | [6.5](/filings/0000950170-24-123445.md) | [10.1 d](/filings/0000950170-25-042759.md) | [9.3](/filings/0000950170-25-064552.md) | [10.5](/filings/0000950170-25-104176.md) | [20.0](/filings/0001193125-25-270012.md) | [19.2 d](/filings/0001193125-26-120873.md) | [11.1](/filings/0001193125-26-213466.md) | [19.8](/filings/0001193125-26-335407.md) | [18.5](/filings/0001193125-25-270012.md) | [24.5 d](/filings/0001193125-26-120873.md) | [20.4](/filings/0001193125-26-213466.md) | [24.4](/filings/0001193125-26-335407.md) |
| Operating income | $m | [(9.9)](/filings/0000950170-24-123445.md) | [(13.6) d](/filings/0000950170-25-042759.md) | [(12.8)](/filings/0000950170-25-064552.md) | [(15.3)](/filings/0000950170-25-104176.md) | [(24.8)](/filings/0001193125-25-270012.md) | [(25.4) d](/filings/0001193125-26-120873.md) | [(16.4)](/filings/0001193125-26-213466.md) | [(24.8)](/filings/0001193125-26-335407.md) | [(23.1)](/filings/0001193125-25-270012.md) | [(28.4) d](/filings/0001193125-26-120873.md) | [(25.4)](/filings/0001193125-26-213466.md) | [(29.3)](/filings/0001193125-26-335407.md) |
| Interest expense | $m | [2.4](/filings/0000950170-24-123445.md) | [2.6 d](/filings/0000950170-25-042759.md) | [1.2](/filings/0000950170-25-064552.md) | [0.4](/filings/0000950170-25-104176.md) | [0.4](/filings/0001193125-25-270012.md) | [0.3 d](/filings/0001193125-26-120873.md) | [0.3](/filings/0001193125-26-213466.md) | [0.2](/filings/0001193125-26-335407.md) | [0.1](/filings/0001193125-25-270012.md) | [0.1 d](/filings/0001193125-26-120873.md) | [0.0](/filings/0001193125-26-213466.md) | [0.0](/filings/0001193125-26-335407.md) |
| Net income | $m | [(14.6)](/filings/0000950170-24-123445.md) | [(21.0) d](/filings/0000950170-25-042759.md) | [(13.0)](/filings/0001193125-25-270012.md) | [(13.6)](/filings/0001193125-25-270012.md) | [(23.4)](/filings/0001193125-25-270012.md) | [(21.1) d](/filings/0001193125-26-120873.md) | [(12.9)](/filings/0001193125-26-335407.md) | [(21.6)](/filings/0001193125-26-335407.md) | [(20.2)](/filings/0001193125-25-270012.md) | [(25.9) d](/filings/0001193125-26-120873.md) | [(22.3)](/filings/0001193125-26-335407.md) | [(26.1)](/filings/0001193125-26-335407.md) |
| Diluted EPS | $ per share | [(8.74)](/filings/0000950170-24-123445.md) | not reported | [(7.76)](/filings/0000950170-25-064552.md) | [(7.94)](/filings/0000950170-25-104176.md) | [(6.70)](/filings/0001193125-25-270012.md) | not reported | [(0.36)](/filings/0001193125-26-213466.md) | [(0.60)](/filings/0001193125-26-335407.md) | [(0.56)](/filings/0001193125-25-270012.md) | not reported | [(0.52)](/filings/0001193125-26-213466.md) | [(0.58)](/filings/0001193125-26-335407.md) |
| Basic EPS | $ per share | [(8.74)](/filings/0000950170-24-123445.md) | not reported | [(7.76)](/filings/0000950170-25-064552.md) | [(7.94)](/filings/0000950170-25-104176.md) | [(6.70)](/filings/0001193125-25-270012.md) | not reported | [(0.36)](/filings/0001193125-26-213466.md) | [(0.60)](/filings/0001193125-26-335407.md) | [(0.56)](/filings/0001193125-25-270012.md) | not reported | [(0.52)](/filings/0001193125-26-213466.md) | [(0.58)](/filings/0001193125-26-335407.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [21.6](/filings/0000950170-25-042759.md) | [174](/filings/0000950170-25-064552.md) | not reported | [334](/filings/0000950170-24-123445.md) | [354](/filings/0001193125-26-120873.md) | [257](/filings/0000950170-25-064552.md) | [220](/filings/0000950170-25-104176.md) | [216](/filings/0001193125-25-270012.md) | [189](/filings/0001193125-26-335407.md) | [242](/filings/0001193125-26-213466.md) | [74.0](/filings/0001193125-26-335407.md) |
| Current assets | $m | not reported | [25.3](/filings/0000950170-25-042759.md) | not reported | not reported | [336](/filings/0000950170-24-123445.md) | [357](/filings/0001193125-26-120873.md) | [325](/filings/0000950170-25-064552.md) | [302](/filings/0000950170-25-104176.md) | [291](/filings/0001193125-25-270012.md) | [287](/filings/0001193125-26-335407.md) | [392](/filings/0001193125-26-213466.md) | [330](/filings/0001193125-26-335407.md) |
| Total assets | $m | not reported | [25.9](/filings/0000950170-25-042759.md) | not reported | not reported | [337](/filings/0000950170-24-123445.md) | [358](/filings/0001193125-26-120873.md) | [344](/filings/0000950170-25-064552.md) | [322](/filings/0000950170-25-104176.md) | [305](/filings/0001193125-25-270012.md) | [295](/filings/0001193125-26-335407.md) | [398](/filings/0001193125-26-213466.md) | [397](/filings/0001193125-26-335407.md) |
| Current liabilities | $m | not reported | [58.2](/filings/0000950170-25-042759.md) | not reported | not reported | [19.1](/filings/0000950170-24-123445.md) | [27.8](/filings/0001193125-26-120873.md) | [23.7](/filings/0000950170-25-064552.md) | [22.8](/filings/0000950170-25-104176.md) | [24.5](/filings/0001193125-25-270012.md) | [20.1](/filings/0001193125-26-335407.md) | [15.8](/filings/0001193125-26-213466.md) | [19.2](/filings/0001193125-26-335407.md) |
| Total liabilities | $m | not reported | [66.6](/filings/0000950170-25-042759.md) | not reported | not reported | [23.6](/filings/0000950170-24-123445.md) | [35.1](/filings/0001193125-26-120873.md) | [30.7](/filings/0000950170-25-064552.md) | [27.4](/filings/0000950170-25-104176.md) | [27.6](/filings/0001193125-25-270012.md) | [22.8](/filings/0001193125-26-335407.md) | [18.5](/filings/0001193125-26-213466.md) | [22.0](/filings/0001193125-26-335407.md) |
| Long-term debt | $m | not reported | [8.2](/filings/0000950170-25-042759.md) | not reported | not reported | [3.9](/filings/0000950170-24-123445.md) | [2.5](/filings/0001193125-26-120873.md) | [1.1](/filings/0000950170-25-064552.md) | [0.0](/filings/0000950170-25-104176.md) | [0.0](/filings/0001193125-25-270012.md) | [0.0](/filings/0001193125-26-120873.md) | not reported | not reported |
| Current portion of debt | $m | not reported | [6.0](/filings/0000950170-25-042759.md) | not reported | not reported | [6.0](/filings/0000950170-24-123445.md) | [6.0](/filings/0001193125-26-120873.md) | [6.0](/filings/0000950170-25-064552.md) | [5.6](/filings/0000950170-25-104176.md) | [4.1](/filings/0001193125-25-270012.md) | [2.6](/filings/0001193125-26-335407.md) | [1.2](/filings/0001193125-26-213466.md) | [0.0](/filings/0001193125-26-335407.md) |
| Shareholders' equity | $m | [(153)](/filings/0000950170-24-123445.md) | [(173)](/filings/0001193125-26-120873.md) | [(186)](/filings/0001193125-25-270012.md) | [(197)](/filings/0001193125-25-270012.md) | [314](/filings/0001193125-25-270012.md) | [323](/filings/0001193125-26-335407.md) | [313](/filings/0001193125-26-335407.md) | [295](/filings/0001193125-26-335407.md) | [277](/filings/0001193125-25-270012.md) | [272](/filings/0001193125-26-335407.md) | [379](/filings/0001193125-26-335407.md) | [375](/filings/0001193125-26-335407.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.5) d](/filings/0000950170-25-042759.md) | [(15.7)](/filings/0000950170-25-064552.md) | [(15.8) d](/filings/0000950170-25-104176.md) | [(14.9) d](/filings/0001193125-25-270012.md) | [(5.1) d](/filings/0001193125-26-120873.md) | [(17.4)](/filings/0001193125-26-213466.md) | [(20.0) d](/filings/0001193125-26-335407.md) | [(16.0) d](/filings/0001193125-25-270012.md) | [(28.3) d](/filings/0001193125-26-120873.md) | [(24.0)](/filings/0001193125-26-213466.md) | [(19.3) d](/filings/0001193125-26-335407.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-25-042759.md) | [0.0](/filings/0000950170-25-064552.md) | [0.0 d](/filings/0000950170-25-104176.md) | [0.3 d](/filings/0001193125-25-270012.md) | [0.0 d](/filings/0001193125-26-120873.md) | [0.4](/filings/0001193125-26-213466.md) | [0.2 d](/filings/0001193125-26-335407.md) | [0.0 d](/filings/0001193125-25-270012.md) | [0.1 d](/filings/0001193125-26-120873.md) | [0.0](/filings/0001193125-26-213466.md) | [0.3 d](/filings/0001193125-26-335407.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.7](/filings/0000950170-24-123445.md) | [1.7](/filings/0000950170-25-064552.md) | [1.7](/filings/0000950170-25-104176.md) | [3.5](/filings/0001193125-25-270012.md) | [35.9](/filings/0001193125-26-213466.md) | [35.9](/filings/0001193125-26-335407.md) | [35.9](/filings/0001193125-25-270012.md) | [42.5](/filings/0001193125-26-213466.md) | [44.8](/filings/0001193125-26-335407.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,896,909 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335407.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.